New England Journal of Medicine publishes primary endpoint analysis from the ongoing Phase 3 study of Takeda’s dengue vaccine candidate. Takeda Pharmaceutical Company Limited (“Takeda”)…
Read More Takeda’s Dengue Vaccine shows Effect in Children ages 4-16 Years